NCT06374797

A Study of Auxora in Patients With AKI and Injurious Lung Crosstalk

Name: Clinical Trial NCT06374797
Creator: CalciMedica, Inc.
Keywords: Acute Kidney Injury, Auxora, Phase 2, drug, clinical trial

Auxora for the Treatment of AKI and Modulation of Injurious Crosstalk With the Lung: A Randomized Control Trial (KOURAGE)

CalciMedica, Inc.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Acute Kidney Injury
Drug/Device/Intervention: Auxora
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: CalciMedica, Inc.

Timeline & enrollment

Phase: Phase 2
Start date: May 01, 2024
End date: Aug 01, 2025
Enrollment: 150 participants

Primary outcome

Days alive, ventilator-free and kidney replacement therapy (KRT)-free from SFISD through Day 30

Summary

Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.

ICD-10 classifications

Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06374797
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06374797 through Pure Global AI's free database. This Phase 2 trial is sponsored by CalciMedica, Inc. and is currently Not yet recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.